

MEDICAL CANNABIS WHY ODENSE

The Top 3 commercial producers of medical cannabis in the world are in Odense: Aurora, Canopy Growth and Aphria

In Odense companies, scientists and the hospital have joined forces to boost business and growth within medical cannabis

At the university in Odense, both the chemical institute and the Institute of molecular biology is involved in science projects made in collaboration with medical cannabis producers.

Spectrum Cannabis has Mark Ware on their Payrole. Mark Ware is a world-renowned pain specialist and medical cannabis researcher, with around 20 years of research in medical cannabis.

Still more suppliers and consultants working with medical cannabis producers see the potential in Denmark and visit Odense to establish business here.

Denmark has a strong brand within horticulture and farming, and a strong brand within pharma. Within Medical Cannabis – as controversial as it is - we need to associate ourselves with strong brands.”

*Lars Thomasson,
Business Development Manager,
Spectrum Cannabis*

Horticulture in Odense

70% of the greenhouses in DK is based on the island of Funen in and around Odense
More than 3,000 people work in Odense's horticulture business

Odense's largest horticulture companies:

Top 4 - 2017	EBIT mill. DKK	Employees
PKM	0,9	167
Rosa Danica	3,4	127
Alfred Pedersen & Søn	2,0	125
ByGrowers	3,9	112

Global MEDICAL CANNABIS MARKET

2017: \$ 7.2 bn
2024: \$ 55.0 bn (expected)

Expected Growth Rate: 36%

German market

2017: \$ 805.5m

Global Market Insights
<https://www.gminsights.com/pressrelease/medical-marijuana-market>

INTERNATIONAL PLAYERS in ODENSE

Aurora Nordic

51 % - Aurora Cannabis Inc., Vancouver Canada

49 % - Alfred Pedersen & Søn
CEO Mads Ulrik Pedersen

Expected turnover per year \$ 305 million per year within 2 years. First products approved for sale, Q3 2019
5,000 square meters currently in use.
50,000 square meters planned

Spectrum Cannabis

51 % - Canopy Growth Corporation, Ontario Canada, 49 % - Danish Cannabis ApS, Rønde. CEO: Morten Larsen Snede

Expected turnover: \$76 million within 2 years.

Expect to sell to around 60,000 patients in Europe. First products approved for sale, Q3 2019. 40,000 square meters planned

Schroll Medical

85% Schroll Medical, 15% Aphria (\$114,000) (Aphria plan to reach 50% First products approved for sale Q3 2019. Two production sites converted from flowers to medical cannabis: The Odense facility, 10,000 square meters (organic cannabis) + facilities in Portugal.